Goodwin Procter LLP advised Repertoire Immune Medicines on the deal. Repertoire Immune Medicines announced the completion of its $189 million Series B financing. Joining Flagship Pioneering, Repertoire’s...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Rubius Therapeutics on the deal. Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Tessera Therapeutics on the deal. Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised...
You must be a Standard 1 Year member to access this content.
